ASPI (ASPI) Stock Analysis
Verdict: AVOID
Severe insider liquidations and explosive operational cash burn overshadow revenue growth, pinning ASPI to its 52-week low of $3.01.
Investment score: 26/100
Is ASPI Stock Worth Reviewing? AI Model Thesis
The AI model rates ASPI as AVOID. Explosive top-line revenue growth is offset by extreme net losses, continuous insider selling, high debt ($215.96M), and technical momentum locked at 52-week lows.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| ECVT | -19.14 | 1.93 | 1.30 | 7.46 | — | -0.07 |
| FTK | 28.60 | 8.51 | 3.76 | 27.21 | — | 0.13 |
| RYAM | -4.39 | 3.17 | 0.42 | 8.68 | — | -0.10 |
| ASPN | -3.71 | 2.45 | 2.33 | -5.95 | — | -0.62 |
| VHI | -9.07 | 0.45 | 0.21 | 10.31 | — | -0.02 |
Should You Buy or Sell ASPI Stock? Model Reasoning
The model assesses ASPI as an AVOID due to severe insider liquidations (24 sell transactions, 0 buys), expanding net losses (-$175.09M in 2025), and a multi-month technical collapse that has brought the share price to its 52-week low of $3.01. While 2025 revenue expanded to $23.85M and cash balances stand at $285.56M, an operating margin of -312.3% and P/S TTM of 12.28x (vs peer median 1.30x–2.33x) offer insufficient margin of safety.
ASPI Fair Value & Price Target — AI Valuation
- Model Assumptions: ["Revenue ramps according to consensus targets: $70M in 2027 (3 analysts) and $260M in 2028 (2 analysts)","Current cash balance of $285.56M prevents immediate highly dilutive equity raises prior to 2027","Gross margins expand from 18.32% in 2025 toward >35% as enriched output reaches industrial scale"]
ASPI Risk & Opportunity Analysis
Key Investment Risks
- Explosive net cash burn and high leverage — Despite top-line gains, net losses expanded from -$32.33M in 2024 to -$175.09M in 2025, driven by operating expenses and interest costs on $215.96M of debt.
- Unrelenting insider distribution signals lack of executive confidence — Insiders executed 24 sell orders in recent months—including CEO Paul Elliot Mann selling over 250,000 shares in June 2026 around $7.76–$8.29—with zero open-market purchases.
- Extremely demanding valuation relative to chemical peers — P/S TTM of 12.28x significantly exceeds peers like ECVT (1.30x) and ASPN (2.33x); any growth deceleration could trigger further contraction toward peer valuation multiples ($0.30–$0.60 price equivalent).
- Technical collapse with zero historical price support below $3.01 — Trading at the 52-week low of $3.01 with 90-day momentum at -50.6%, the stock lacks defined structural support, risking further breakdown into microcap penny status.
Growth Opportunities & Upside Drivers
- Rapid top-line acceleration in advanced materials — Annual revenue grew from $4.14M in 2024 to $23.849M in 2025 (+573.35%), demonstrating initial commercial adoption for specialized isotope products.
- Substantial gross cash cushion provides runway — Cash reserves of $285.56M as of December 2025 offset annual operating cash burn (-$37.78M in 2025), extending cash runway beyond 48 months if capital expenditures remain constrained.
- Turnaround potential in forward analyst estimates — Consensus forward estimates project EPS turning positive at $0.74 by 2028 on $260M revenue, offering potential multi-year upside if commercial scale-up is achieved.
- High short-term rebound potential on positive clinical/nuclear milestones — With a Beta of 3.74 and shares 79.2% off their 52-week high of $14.49, any positive regulatory or supply agreement could spark rapid speculative price bounces.
ASPI Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About ASPI (ASPI)
Is ASPI stock a good investment?
The cached TradeMates AI model rates ASPI as AVOID with an investment score of 26/100. The AI model rates ASPI as AVOID. Explosive top-line revenue growth is offset by extreme net losses, continuous insider selling, high debt ($215.96M), and technical momentum locked at 52-week lows. This is algorithmic model output, not personal investment advice.
Does ASPI pay a dividend?
The cached stock data on this page does not show a positive dividend yield for ASPI. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does ASPI stock do?
Advanced materials technology firm utilizing proprietary Aerodynamic Separation Process (ASP) to enrich isotopes including Molybdenum-100 (medical imaging), Silicon-28 (semiconductors), Carbon-14, and Uranium-235/HALEU (advanced nuclear energy).
What is ASPI stock's price target?
This cached page does not contain a precise model fair value for ASPI.
Is ASPI stock a buy?
The TradeMates model verdict for ASPI is AVOID with an investment score of 26/100. Treat this as a model signal to review, not a personal buy recommendation.
Is ASPI a good dividend stock?
ASPI is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.